2023
Corrigendum to ‘Maintenance on extended-release naltrexone is associated with reduced injection opioid use among justice-involved persons with opioid use disorder’ [J. Subst. Abuse Treat. vol. 142 (2022)/108852]
Lier A, Seval N, Vander Wyk B, Di Paola A, Springer S. Corrigendum to ‘Maintenance on extended-release naltrexone is associated with reduced injection opioid use among justice-involved persons with opioid use disorder’ [J. Subst. Abuse Treat. vol. 142 (2022)/108852]. Journal Of Substance Use And Addiction Treatment 2023, 150: 209074. PMID: 37271717, DOI: 10.1016/j.josat.2023.209074.Peer-Reviewed Original Research
2021
Long-acting buprenorphine vs. naltrexone opioid treatments in CJS-involved adults (EXIT-CJS)
Waddell EN, Springer SA, Marsch LA, Farabee D, Schwartz RP, Nyaku A, Reeves R, Goldfeld K, McDonald RD, Malone M, Cheng A, Saunders EC, Monico L, Gryczynski J, Bell K, Harding K, Violette S, Groblewski T, Martin W, Talon K, Beckwith N, Suchocki A, Torralva R, Wisdom JP, Lee JD. Long-acting buprenorphine vs. naltrexone opioid treatments in CJS-involved adults (EXIT-CJS). Journal Of Substance Use And Addiction Treatment 2021, 128: 108389. PMID: 33865691, PMCID: PMC8384640, DOI: 10.1016/j.jsat.2021.108389.Peer-Reviewed Original ResearchConceptsOpioid use disorderSelf-reported opioid useOpioid-positive urine samplesExtended-release buprenorphineExtended-release naltrexoneOpioid overdose eventsXR-NTXOpioid treatmentObservational cohortOpioid useUsual armCare outcomesUse disordersNoninferiority designOverdose eventsUrine samplesBuprenorphineTreatmentAdultsEnhanced treatmentNaltrexoneRCTsCohortU.S. localesTrialsChapter 10 Inpatient opioid use disorder treatment for the infectious disease physician
Seval N, Eaton E, Springer S. Chapter 10 Inpatient opioid use disorder treatment for the infectious disease physician. 2021, 189-221. DOI: 10.1016/b978-0-323-68328-9.00010-2.Peer-Reviewed Original ResearchOpioid use disorderInfectious disease physiciansDisease physiciansOpioid use disorder treatmentInitiation of medicationOpioid-related conditionsUse disorder treatmentEvidence-based treatmentsPatient-centered conceptsID consultationTreatment interruptionAcute painUse disordersOUD managementDisorder treatmentInfectionTreatmentPhysiciansCareMedicationsPainBuprenorphineNaltrexoneMethadoneDiagnosis
2020
A systematic review of patients' and providers' perspectives of medications for treatment of opioid use disorder
Cioe K, Biondi BE, Easly R, Simard A, Zheng X, Springer SA. A systematic review of patients' and providers' perspectives of medications for treatment of opioid use disorder. Journal Of Substance Use And Addiction Treatment 2020, 119: 108146. PMID: 33138929, PMCID: PMC7609980, DOI: 10.1016/j.jsat.2020.108146.Peer-Reviewed Original ResearchConceptsOpioid use disorderOpioid epidemicProvider perspectivesUse disordersSystematic reviewType of MOUDExtended-release naltrexoneNumber of patientsOutcomes of interestPubMed database searchReview eligibility criteriaPatient themesPublic health crisisPatient retentionMOUDEligibility criteriaPatientsProviders' perceptionsFinal reviewLack of trainingMedicationsBuprenorphineNaltrexoneMethadoneHealth crisis
2019
Medications for Treatment of Opioid Use Disorder among Persons Living with HIV
Fanucchi L, Springer SA, Korthuis PT. Medications for Treatment of Opioid Use Disorder among Persons Living with HIV. Current HIV/AIDS Reports 2019, 16: 1-6. PMID: 30684117, PMCID: PMC6420833, DOI: 10.1007/s11904-019-00436-7.Peer-Reviewed Original ResearchConceptsOpioid use disorderExtended-release naltrexoneHIV treatment outcomesHIV viral suppressionViral suppressionUse disordersAntiretroviral therapyTreatment outcomesCurrent US opioid epidemicOptimal HIV treatment outcomesUS opioid epidemicOverall mortalityHIV outbreakHIV treatmentOpioid epidemicMOUDHIVMedicationsDisordersNaltrexoneDelivery characteristicsTherapyTreatmentIncarcerated settingsOutcomes
2018
Extended-release Naltrexone Improves Viral Suppression Among Incarcerated Persons Living with HIV and Alcohol use Disorders Transitioning to the Community
Springer SA, Di Paola A, Barbour R, Azar MM, Altice FL. Extended-release Naltrexone Improves Viral Suppression Among Incarcerated Persons Living with HIV and Alcohol use Disorders Transitioning to the Community. JAIDS Journal Of Acquired Immune Deficiency Syndromes 2018, 79: 92-100. PMID: 29781884, PMCID: PMC6092223, DOI: 10.1097/qai.0000000000001759.Peer-Reviewed Original ResearchConceptsAlcohol use disorderViral suppressionExtended-release naltrexoneXR-NTXPlacebo groupPlacebo-controlled trialMonthly injectionsSecondary outcomesTreat analysisIncarcerated individualsEligible participantsWhite raceUse disordersAlcohol consumptionHIVMonthsNaltrexoneBaselineDisordersInjectionIncarcerated peopleParticipantsPlaceboGroupSuppressionExtended-Release Naltrexone Improves Viral Suppression Among Incarcerated Persons Living With HIV With Opioid Use Disorders Transitioning to the Community
Springer SA, Di Paola A, Azar M, Barbour R, Biondi BE, Desabrais M, Lincoln T, Skiest DJ, Altice FL. Extended-Release Naltrexone Improves Viral Suppression Among Incarcerated Persons Living With HIV With Opioid Use Disorders Transitioning to the Community. JAIDS Journal Of Acquired Immune Deficiency Syndromes 2018, 78: 43-53. PMID: 29373393, PMCID: PMC5889326, DOI: 10.1097/qai.0000000000001634.Peer-Reviewed Original ResearchMeSH KeywordsAdultCriminal LawDelayed-Action PreparationsDouble-Blind MethodFemaleFollow-Up StudiesHIV InfectionsHIV-1HumansInjections, IntramuscularMaleMiddle AgedMultivariate AnalysisNaltrexoneNarcotic AntagonistsOpioid-Related DisordersPrisonersProspective StudiesResearch DesignRNA, ViralTime FactorsTreatment OutcomeViral LoadConceptsOpioid use disorderViral suppressionXR-NTXPlacebo groupPrimary outcomeUse disordersXR-NTX groupPlacebo-controlled trialExtended-release naltrexoneStatistical significant differenceRelease naltrexoneMonthly injectionsEligible participantsTreatment groupsJail detaineesHIVMonthsBaselinePlaceboSignificant differencesNaltrexoneJail inmatesDisordersVS levelsOutcomesA qualitative assessment of attitudes about and preferences for extended-release naltrexone, a new pharmacotherapy to treat opioid use disorders in Ukraine
Marcus R, Bojko MJ, Mazhnaya A, Makarenko I, Filippovych S, Dvoriak S, Altice FL, Springer SA. A qualitative assessment of attitudes about and preferences for extended-release naltrexone, a new pharmacotherapy to treat opioid use disorders in Ukraine. Journal Of Substance Use And Addiction Treatment 2018, 86: 86-93. PMID: 29415856, PMCID: PMC5808584, DOI: 10.1016/j.jsat.2018.01.003.Peer-Reviewed Original ResearchConceptsOpioid agonist therapyXR-NTXExtended-release naltrexonePsychological supportOpioid use disorderHIV prevention effortsFocus groupsPerceptions of recoveryAgonist therapyOpioid withdrawalYoung PWIDOpioid antagonistPatient preferencesNew pharmacotherapiesPsychoactive medicationsInjection careerUse disordersFocus group transcriptsPWIDPrevention effortsNaltrexoneGroup transcriptsIndividual barriersTreatmentWithdrawal
2017
Patient preferences and extended-release naltrexone: A new opportunity to treat opioid use disorders in Ukraine
Marcus R, Makarenko I, Mazhnaya A, Zelenev A, Polonsky M, Madden L, Filippovych S, Dvoriak S, Springer SA, Altice FL. Patient preferences and extended-release naltrexone: A new opportunity to treat opioid use disorders in Ukraine. Drug And Alcohol Dependence 2017, 179: 213-219. PMID: 28806638, PMCID: PMC5599372, DOI: 10.1016/j.drugalcdep.2017.07.010.Peer-Reviewed Original ResearchConceptsOpioid agonist therapyOpioid use disorderExtended-release naltrexoneXR-NTXHIV preventionIndependent correlatesPatient preferencesUse disordersShort-term injectorsPatient-centered treatmentAgonist therapyPharmacological therapyHIV incidenceTreatment optionsPWIDTreatment entryAddiction treatmentPreventionNaltrexoneShort durationTherapyNegative attitudesDisordersNew optionsTreatmentCorrigendum to “Design and methods of a double blind randomized placebo-controlled trial of extended-release naltrexone for alcohol dependent and hazardous drinking prisoners with HIV who are transitioning to the community” [Contemp. Clin. Trials (2014) 209–218]
Springer SA, Altice FL, Herme M, Di Paola A. Corrigendum to “Design and methods of a double blind randomized placebo-controlled trial of extended-release naltrexone for alcohol dependent and hazardous drinking prisoners with HIV who are transitioning to the community” [Contemp. Clin. Trials (2014) 209–218]. Contemporary Clinical Trials 2017, 57: 98. PMID: 28341227, DOI: 10.1016/j.cct.2017.03.008.Peer-Reviewed Original ResearchCorrigendum to ‘An evaluation of hepatic enzyme elevations among HIV-infected released prisoners enrolled in two randomized placebo-controlled trials of extended release naltrexone’ [Journal of Substance Abuse Treatment 47 (2014) 35–40]
Vagenas P, Di Paola A, Herme M, Lincoln T, Skiest DJ, Altice FL, Springer SA. Corrigendum to ‘An evaluation of hepatic enzyme elevations among HIV-infected released prisoners enrolled in two randomized placebo-controlled trials of extended release naltrexone’ [Journal of Substance Abuse Treatment 47 (2014) 35–40]. Journal Of Substance Use And Addiction Treatment 2017, 77: 44. PMID: 28476270, PMCID: PMC5458355, DOI: 10.1016/j.jsat.2017.03.008.Peer-Reviewed Original ResearchExtended-release naltrexone reduces alcohol consumption among released prisoners with HIV disease as they transition to the community
Springer SA, Di Paola A, Azar MM, Barbour R, Krishnan A, Altice FL. Extended-release naltrexone reduces alcohol consumption among released prisoners with HIV disease as they transition to the community. Drug And Alcohol Dependence 2017, 174: 158-170. PMID: 28334661, PMCID: PMC5407009, DOI: 10.1016/j.drugalcdep.2017.01.026.Peer-Reviewed Original ResearchConceptsHeavy drinking daysAlcohol use disorderFirst heavy drinking dayExtended-release naltrexoneXR-NTXDrinking daysPlacebo groupAlcohol consumptionDrinks/drinking dayPlacebo-controlled trialSerious adverse eventsDrinks/daySignificant differencesMonthly injectionsAdverse eventsHIV diseaseHIV outcomesTreatment armsAlcohol scoresMAIN OUTCOMEAlcohol consumption scoresUse disordersImprovement scoresDrinking outcomesNaltrexone
2016
Erratum to “Correlates of retention on extended-release naltrexone among persons living with HIV infection transitioning to the community from the criminal justice system” [Drug Alcohol Depend. 157 (2015) 158–165]
Springer S, Brown S, Di Paola A. Erratum to “Correlates of retention on extended-release naltrexone among persons living with HIV infection transitioning to the community from the criminal justice system” [Drug Alcohol Depend. 157 (2015) 158–165]. Drug And Alcohol Dependence 2016, 161: 372. PMID: 28463553, PMCID: PMC4871258, DOI: 10.1016/j.drugalcdep.2016.02.009.Peer-Reviewed Original Research
2014
An evaluation of hepatic enzyme elevations among HIV-infected released prisoners enrolled in two randomized placebo-controlled trials of extended release naltrexone
Vagenas P, Di Paola A, Herme M, Lincoln T, Skiest DJ, Altice FL, Springer SA. An evaluation of hepatic enzyme elevations among HIV-infected released prisoners enrolled in two randomized placebo-controlled trials of extended release naltrexone. Journal Of Substance Use And Addiction Treatment 2014, 47: 35-40. PMID: 24674234, PMCID: PMC4042403, DOI: 10.1016/j.jsat.2014.02.008.Peer-Reviewed Original ResearchConceptsPlacebo-controlled trialXR-NTXGamma-glutamyl transferaseAlanine aminotransferaseMental illnessAspartate aminotransferaseRandomized placebo-controlled trialMonthly injectable formulationXR-NTX armExtended-release naltrexoneHepatic enzyme elevationHepatic enzyme levelsRelease naltrexoneAntiretroviral therapyHCV infectionBaseline characteristicsHepatic transaminasesEnzyme elevationPsychiatric medicationsHepatotoxicity concernsGlutamyl transferaseAlcohol dependenceOpioidsHIVNaltrexone
2013
Design and methods of a double blind randomized placebo-controlled trial of extended-release naltrexone for alcohol dependent and hazardous drinking prisoners with HIV who are transitioning to the community
Springer SA, Altice FL, Herme M, Di Paola A. Design and methods of a double blind randomized placebo-controlled trial of extended-release naltrexone for alcohol dependent and hazardous drinking prisoners with HIV who are transitioning to the community. Contemporary Clinical Trials 2013, 37: 209-218. PMID: 24384538, PMCID: PMC3992862, DOI: 10.1016/j.cct.2013.12.006.Peer-Reviewed Original ResearchConceptsPlacebo-controlled trialHIV treatment outcomesTreatment outcomesCriminal justice system (CJS) populationsPoor antiretroviral therapy (ART) adherenceAlcohol useExtended-release naltrexoneAntiretroviral therapy adherenceMedication-assisted therapyPrevention of relapseAlcohol use disorderSexual risk-taking behaviorsAlcohol-dependent personsXR-NTXHigh morbidityTherapy adherenceAlcohol relapseHigh prevalenceStudy participationEligibility criteriaUse disordersHIVRelapseHazardous drinkingNaltrexone
2010
HIV, alcohol dependence, and the criminal justice system: a review and call for evidence-based treatment for released prisoners
Springer SA, Azar MM, Altice FL. HIV, alcohol dependence, and the criminal justice system: a review and call for evidence-based treatment for released prisoners. The American Journal Of Drug And Alcohol Abuse 2010, 37: 12-21. PMID: 21171933, PMCID: PMC3070290, DOI: 10.3109/00952990.2010.540280.BooksConceptsAlcohol use disorderHIV treatment outcomesTreatment outcomesAlcohol dependencePoor HIV treatment outcomesRole of pharmacotherapyRelationship of HIVHIV risk behaviorsBetter treatment outcomesEvidence-based treatmentsAntiretroviral therapySignificant morbidityTherapeutic optionsPoor adherenceAlcohol abuseHIVUse disordersHIV cycleCommunity settingsRisk behaviorsAlcohol usePrimary articlesImproved treatmentVulnerable populationsNaltrexone